@entity242 is a rare histologic subtype of @entity242 . The clinical behavior and prognostic factors influencing survival in this disease are examined. A review of clinicopathologic features of @entity1 with @entity242 prospectively followed between September 1981 and April 2001 at the @entity5 Institute Hospital was performed. Eight @entity1 (4 @entity1 and 4 @entity1 ) constituted the subjects of this study, with a mean age of 41 years. @entity5 presented in the lower extremity in 62.5% of @entity1 and in the upper extremity in 37.5%. All @entity1 were followed for at least 10 years from the time of diagnosis or until @entity204 . The follow-up ranged from 17 to 228 months, with a mean of 78 months. At least one local recurrence was seen in 50% of @entity1 . During the course of the disease, @entity3 to regional lymph nodes developed in 50% of @entity1 and @entity3 to the lungs in 62.5%. The median survival was 31 months, with a 25% 5-year and 10-year survival rate. Pulmonary @entity3 were correlated with decreased survival. A delay in diagnosis of @entity242 is common. @entity242 differs from other @entity242 subtypes in its propensity for nodal spread and local recurrence. Chemotherapy and radiotherapy have an insignificant effect on the course of @entity242 . Careful follow-up, evaluating local recurrence, nodal spread, and pulmonary @entity3 , is warranted. The long-term outcome of @entity242 is dismal.

XXXX of the extremities: a dismal long-term outcome.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'epithelioid sarcoma', 'Epithelioid sarcoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumors', 'Cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity242 :: (MESH:D012509,Disease) :: ['Epithelioid sarcoma']
